Compass Therapeutics (CMPX) Operating Leases: 2023-2025
Historic Operating Leases for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $9.9 million.
- Compass Therapeutics' Operating Leases rose 43.48% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year increase of 43.48%. This contributed to the annual value of $6.3 million for FY2024, which is 1074.63% up from last year.
- As of Q3 2025, Compass Therapeutics' Operating Leases stood at $9.9 million, which was down 0.37% from $9.9 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Operating Leases registered a high of $9.9 million during Q2 2025, and its lowest value of $536,000 during Q4 2023.
- Over the past 3 years, Compass Therapeutics' median Operating Leases value was $2.6 million (recorded in 2023), while the average stood at $4.5 million.
- Data for Compass Therapeutics' Operating Leases shows a peak YoY increase of 1,074.63% (in 2024) and a maximum YoY decrease of 53.58% (in 2024) over the last 5 years.
- Quarterly analysis of 3 years shows Compass Therapeutics' Operating Leases stood at $536,000 in 2023, then skyrocketed by 1,074.63% to $6.3 million in 2024, then spiked by 43.48% to $9.9 million in 2025.
- Its Operating Leases was $9.9 million in Q3 2025, compared to $9.9 million in Q2 2025 and $6.4 million in Q1 2025.